Members of our executive management have played leading roles in the development and commercialization of multiple significant drugs in a wide range of therapeutic areas.
Dr. Went, founding CEO and Chairman of Adamas Pharmaceuticals, has overseen the development of the company since its inception. Previously, Dr. Went co-founded CuraGen Corporation in 1992, where he served as an Executive Vice President and Director. Dr. Went received his Ph.D. in Chemical Engineering from the University of California, Berkeley, and a B.S. in Chemical Engineering from Carnegie Mellon University. Dr. Went is the author of 28 papers and an inventor on more than 70 issued patents and pending applications.
Mr. Dawson joined the company in August 2014. Before coming to Adamas, he was a consultant to a number of companies, including Adamas. Previously he served as Chief Financial Officer at Catalyst Biosciences, Inc. Prior to Catalyst, he was VP-Finance and CFO of Cerus Corporation. Mr. Dawson also spent over 25 years in senior financial positions at several companies, including McKesson Corporation and Volpe Brown Whelan & Company LLC in the healthcare and biosciences industry. He also serves on the board of directors of McGrath RentCorp and Wellington Trust Company, a subsidiary of Wellington Management Company, LLP. Mr. Dawson received a Bachelor’s degree from Stanford’s School of Engineering and an M.B.A. from Harvard Business School.
Mr. King joined the company in April 2017. Before coming to Adamas, Mr. King was Chief Operating Officer at The Scripps Research Institute. He previously served as president and CEO of AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company developing new pain medications. Prior to AcelRx, he was President, Chief Operating Officer and general manager of the biotechnology company Tercica, Inc. (later sold to the Ipsen Group), where he was instrumental in the commercial launch of Dysport® (abobotulinumtoxinA) and Increlex™ (rhlGF-1). He also previously served as Executive Vice President of Commercial Operations at Kos Pharmaceuticals, Inc., where he oversaw the growth of Niaspan® (niacin extended-release) and the launch of Advicor® (niacin extended-release/lovastatin). He was Senior Vice President of Commercial Operations at Solvay and Vice President of Commercial Operations at Unimed, where he launched AndroGel® (testosterone gel). Mr. King received a B.Sc. in chemical engineering from the University of Surrey in the U.K. and an M.B.A. from the Manchester Business School in the U.K.
Dr. Patni joined Adamas as Chief Medical Officer in June 2015. Dr. Patni brings over 15 years of global drug development experience across multiple therapeutic areas as well as extensive knowledge of the drug approval process. Prior to joining Adamas, Dr. Patni served as Chief Development Officer at Ocera Therapeutics. Earlier in his career, he served as SVP (Chief Medical Officer) at Actelion US Pharmaceuticals, Executive Director/VP (Product Lifecycle Team Leader, Therapeutic Area Head) at Roche Pharmaceuticals, and Senior Medical Director (Development Team Leader) at Novartis and Pfizer Pharmaceuticals. Dr. Patni earned a B.S. from the City University of New York Sophie Davis School of Biomedical Education (accelerated BS/MD Program) and an M.D. from the Mount Sinai School of Medicine. He completed his residency and fellowship in internal medicine and cardiology at the Albert Einstein College of Medicine in New York, where he was also an attending physician.
Ms. McConville joined Adamas in December 2014. Previously she was a principal at Stafford McConville Human Resources Partners, a consulting firm, from 2013 until 2014, and prior to that an independent consultant from 2011 until 2013. In addition, she has held senior management positions in human resources for over 20 years, including serving as Senior Director, Human Resources at Onyx Pharmaceuticals and Director, Human Resources at Chiron. Ms. McConville has broad experience in all aspects of human resource operations and integration of corporate transactions. Ms. McConville has provided consulting services to organizations within the biopharmaceutical, cleantech, and non-profit sectors. Ms. McConville holds a BA in Management from Saint Mary’s College of California.
Ms. Rhodes joined as our General Counsel and Corporate Secretary in April 2016. She previously served as General Counsel at Medivation, Inc., where she was responsible for Medivation’s legal matters and also served as Corporate Secretary and as Chief Compliance Officer. Before Medivation, Ms. Rhodes was an Assistant General Counsel at Pfizer Inc., where she supported the U.S. Primary Care Business and its Primary Care Medicines Development Group and served as a global product lead for Pfizer Inc.’s primary care medicines. Prior to joining Pfizer, Ms. Rhodes was an associate in the regulatory law and international trade practice areas at Weil, Gotshal & Manges, LLP. She also served as a law clerk for Chief Judge Gregory A. Carman on the United States Court of International Trade. Ms. Rhodes received a J.D. from Wake Forest University School of Law and a B.A. in Economics from Newcomb College of Tulane University.